Hindustan Foods Ltd
Hindustan Foods Limited is an India-based company, which is engaged in contract manufacturing of various FMCG products including food, home care, personal care, beverages etc. They also do manufacturing of leather shoes and accessories
- Market Cap ₹ 6,088 Cr.
- Current Price ₹ 532
- High / Low ₹ 686 / 461
- Stock P/E 71.5
- Book Value ₹ 58.9
- Dividend Yield 0.00 %
- ROCE 14.4 %
- ROE 15.7 %
- Face Value ₹ 2.00
Pros
- Company has delivered good profit growth of 45.8% CAGR over last 5 years
- Company's median sales growth is 56.9% of last 10 years
Cons
- Stock is trading at 9.05 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: FMCG Industry: Diversified - Large
Part of BSE Allcap BSE SmallCap BSE Fast Moving Consumer Goods Nifty Total Market Nifty Microcap 250
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Sep 2013 | Mar 2014 6m | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6 | 3 | 17 | 24 | 38 | 139 | 492 | 772 | 1,407 | 2,021 | 2,383 | 2,381 | 2,587 | |
6 | 4 | 23 | 22 | 35 | 128 | 459 | 716 | 1,317 | 1,905 | 2,236 | 2,219 | 2,402 | |
Operating Profit | -0 | -0 | -6 | 2 | 3 | 10 | 33 | 56 | 90 | 115 | 147 | 163 | 185 |
OPM % | -0% | -15% | -33% | 9% | 8% | 7% | 7% | 7% | 6% | 6% | 6% | 7% | 7% |
0 | 0 | 11 | 0 | 0 | 1 | 1 | 1 | 3 | 5 | 5 | 10 | 16 | |
Interest | 1 | 1 | 2 | 1 | 1 | 1 | 8 | 11 | 19 | 20 | 27 | 38 | 46 |
Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 7 | 11 | 19 | 24 | 29 | 39 | 46 |
Profit before tax | -1 | -1 | 2 | -0 | 1 | 9 | 18 | 35 | 54 | 77 | 96 | 96 | 110 |
Tax % | 4% | 0% | 0% | -2,980% | 19% | 27% | 35% | 34% | 28% | 35% | 33% | 19% | |
-1 | -1 | 2 | 1 | 1 | 6 | 12 | 23 | 39 | 50 | 65 | 78 | 85 | |
EPS in Rs | -0.48 | -0.53 | 1.00 | 0.58 | 0.10 | 0.97 | 1.76 | 2.14 | 3.71 | 4.44 | 5.72 | 6.83 | 7.46 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 94% |
5 Years: | 37% |
3 Years: | 19% |
TTM: | 11% |
Compounded Profit Growth | |
---|---|
10 Years: | 51% |
5 Years: | 46% |
3 Years: | 26% |
TTM: | 17% |
Stock Price CAGR | |
---|---|
10 Years: | 47% |
5 Years: | 34% |
3 Years: | 14% |
1 Year: | 0% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | 17% |
Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Sep 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 | 13 | 13 | 13 | 21 | 21 | 23 | 23 | 23 | 23 |
Reserves | -8 | -9 | -7 | -5 | 19 | 24 | 51 | 166 | 235 | 285 | 349 | 605 | 651 |
17 | 18 | 11 | 13 | 5 | 34 | 100 | 165 | 219 | 274 | 349 | 508 | 460 | |
4 | 6 | 8 | 7 | 13 | 46 | 102 | 188 | 265 | 305 | 356 | 402 | 507 | |
Total Liabilities | 19 | 20 | 17 | 19 | 50 | 118 | 266 | 540 | 741 | 886 | 1,076 | 1,537 | 1,642 |
4 | 8 | 9 | 9 | 9 | 39 | 133 | 250 | 308 | 396 | 402 | 593 | 586 | |
CWIP | 5 | 3 | 2 | 2 | 3 | 3 | 0 | 26 | 53 | 9 | 45 | 5 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 7 | 80 | 84 | 127 |
10 | 9 | 6 | 8 | 38 | 75 | 133 | 261 | 377 | 474 | 549 | 855 | 929 | |
Total Assets | 19 | 20 | 17 | 19 | 50 | 118 | 266 | 540 | 741 | 886 | 1,076 | 1,537 | 1,642 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Sep 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1 | 3 | 1 | 1 | -5 | -5 | -5 | 17 | 73 | 54 | 102 | 48 | |
-5 | -3 | -1 | -1 | -14 | -19 | -40 | -145 | -91 | -103 | -167 | -347 | |
6 | -0 | 0 | 0 | 24 | 26 | 43 | 153 | 34 | 32 | 47 | 294 | |
Net Cash Flow | 0 | -0 | 0 | 0 | 5 | 2 | -2 | 24 | 16 | -17 | -18 | -6 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Sep 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 224 | 390 | 47 | 56 | 66 | 76 | 32 | 18 | 13 | 13 | 13 | 15 |
Inventory Days | 136 | 295 | 108 | 37 | 90 | 139 | 54 | 74 | 58 | 52 | 61 | 87 |
Days Payable | 183 | 387 | 184 | 103 | 166 | 237 | 85 | 94 | 74 | 60 | 58 | 67 |
Cash Conversion Cycle | 177 | 298 | -29 | -10 | -10 | -21 | 1 | -2 | -3 | 5 | 16 | 35 |
Working Capital Days | 134 | 107 | -9 | 13 | 36 | 51 | 6 | 11 | 16 | 25 | 27 | 55 |
ROCE % | -2% | -6% | 34% | 8% | 7% | 19% | 22% | 18% | 18% | 18% | 19% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
6h - Transcript of Analyst/Investors conference call for Q2 FY '25.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
13 Nov - Submission of audio recording of investor conference call.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Nov
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
12 Nov - Exchanges that, the officials of the Company will be attending the Meeting with Investors/Analysts (Participants), the details of which are mentioned in attached PDF file.
-
Compliances- Statement Of Deviation Or Variation In The Use Of Proceeds Raised Through Preferential Issue
12 Nov - Statement confirming no deviation in fund usage.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptNotesPPT
-
Jul 2020TranscriptNotesPPT
-
Jul 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
Mar 2018TranscriptNotesPPT
Acquired by Van group[1] Hindustan Food Limited (HFL) started a joint venture between Glaxo Smith Kline and the Dempo group to manufacture a nutritional food product under the brand name of ‘Farex’ but the venture made losses for many years as it was dependent on a single brand. In 2013, Dempo Foods Pvt. Ltd., the Holding Company of Hindustan Foods Ltd was acquired by Vanity Case India Pvt. Ltd., and the latter bought 74.45% of the paid-up share capital.